Gmt Capital Corp Avrobio, Inc. Transaction History

Gmt Capital Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$0.58 - $1.31 $1.13 Million - $2.55 Million	-1,945,844 Reduced 44.65%	2,412,015 $2.29 Million
Q1 2023 May 09, 2023	BUY	$0.76 - $1.82 $796,480 - $1.91 Million	1,048,000 Added 31.66%	4,357,859 $4.36 Million
Q4 2022 Feb 03, 2023	SELL	$0.64 - $0.91 $118,163 - $168,014	-184,631 Reduced 5.28%	3,309,859 $2.35 Million
Q2 2022 Aug 10, 2022	BUY	$0.75 - $1.33 $674,682 - $1.2 Million	899,576 Added 34.67%	3,494,490 $3.22 Million
Q4 2021 Feb 11, 2022	BUY	$3.45 - $6.05 $1.59 Million - $2.79 Million	461,700 Added 21.64%	2,594,914 $9.99 Million
Q2 2021 Aug 13, 2021	BUY	$7.84 - $12.6 $4.47 Million - $7.19 Million	570,738 Added 36.53%	2,133,214 $19 Million
Q1 2021 May 13, 2021	BUY	$10.54 - $19.3 $16.5 Million - $30.2 Million	1,562,476 New	1,562,476 $19.8 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Gmt Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Gmt Capital Corp with notifications on news.